Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
Novavax has demonstrated its ability to quickly develop viable vaccine candidates for emerging infectious diseases such as COVID-19.
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious diseases globally through the discovery and development of innovative vaccines to patients around the world.Build your future with us
Join other passionately curious people who are bringing innovative vaccines to the world
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
COVID-Influenza combination (CIC) investigational vaccine
COVID-19 + seasonal influenza
About the candidate
The Novavax COVID-In uenza combination investigational vaccine uses the full-length, stabilized recombinant spike (rS) protein of the SARS-CoV-2 virus, and 4 wild-type recombinant Hemagglutinin (rHA) proteins from the influenza virus, as antigens. Antigens are organized into distinct nanoparticle complexes recognized by the immune system, working in concert with our Matrix-M™ adjuvant.1
- 1Genes inserted into insect baculovirus
SARS-CoV-2 spike and four Influenza Hemagglutinin (HA) genes (H1, H3, B-Y, B-V) are engineered into baculovirus for independent expression.
PDB IDs: 1NNB, 4O5N
H1: Influenza A (H1N1)
B-Y: Influenza B Yamagata lineage
H3: Influenza A (H3N2)
B-V: Influenza B Victoria lineage
- 2Sf9 cells infected
Recombinant baculovirus infects moth cells in the S. frugiperda (Sf9) expression system.
- 3DNA enters Sf9 cell nucleus
Spike or HA DNA is transcribed.
- 4Sf9 cells produce proteins
Proteins are each expressed in their native conformation.
- 5Nanoparticle formation
Proteins are harvested. Vaccine nanoparticles assemble as proteins arranged around a Polysorbate 80 (PS80) core.
- 6Final vaccine
Spike and HA vaccine nanoparticles are mixed with Matrix-M™ adjuvant to create the ready-to-use vaccine.
Why it matters
Combination vaccines reduce the number of shots required to help protect against multiple diseases.. Simplifying immunizations into fewer shots may make it more likely that people get recommended vaccinations on time, reducing delays in protection.2, 3 As both influenza and SARS-CoV-2 continue to circulate and evolve, combining these vaccines into a single shot could offer protection against both diseases. We believe that COVID-19 may become endemic and therefore may require seasonal vaccination, similar to the influenza vaccine.
- Massare, et al. Pre-Print. Available at:https://www.biorxiv.org/content/10.1101/2021.05.05.442782v1 [Accessed 25 Jan 2023].
- US CDC. Available at: https://www.cdc.gov/vaccines/parents/why-vaccinate/combination-vaccines.html [Accessed 27 Aug 2021].
- Skibinski D, et al. Glob Infect Dis. 2011;3(1):63–72. Available at: https://pubmed.ncbi.nlm.nih.gov/21572611/ [Accessed 4 Jan 2022].